Table 3.
KEGG pathway enrichment analysis of target genes under study. Total = total number of genes participating in pathway, Expected = minimum number of genes to be considered as statistically significant, Hits = total number of hits in pathway, False Discovery rate (FDR) = adjusted p-value.
| KEGG Pathways | Total | Expected | Hits | P.Value | FDR |
|---|---|---|---|---|---|
| p53 signaling pathway | 72 | 0.307 | 9 | 1.01e−11 | 3.21e−09 |
| Cellular senescence | 160 | 0.682 | 11 | 2.74e−11 | 4.36e−09 |
| FoxO signaling pathway | 132 | 0.563 | 10 | 9.84e−11 | 1.04e−08 |
| HTLV-I infection | 219 | 0.934 | 11 | 8.15e−10 | 6.48e−08 |
| Endometrial cancer | 58 | 0.247 | 7 | 3.36e−09 | 2.14e−07 |
| Prostate cancer | 97 | 0.414 | 8 | 4.89e−09 | 2.59e−07 |
| Pathways in cancer | 530 | 2.26 | 14 | 1.03e−08 | 4.68e−07 |
| Bladder cancer | 41 | 0.175 | 6 | 1.51e−08 | 5.59e−07 |
| Melanoma | 72 | 0.307 | 7 | 1.58e−08 | 5.59e−07 |
| Progesterone-mediated oocyte maturation | 99 | 0.422 | 7 | 1.48e−07 | 4.69e−06 |
| Thyroid cancer | 37 | 0.158 | 5 | 4.07e−07 | 1.18e−05 |
| Glioma | 75 | 0.32 | 6 | 6.1e−07 | 1.57e−05 |
| Chronic myeloid leukemia | 76 | 0.324 | 6 | 6.6e−07 | 1.57e−05 |
| Cell cycle | 124 | 0.529 | 7 | 6.93e−07 | 1.57e-05 |
| Colorectal cancer | 86 | 0.367 | 6 | 1.38e−06 | 2.85e−05 |
| Viral carcinogenesis | 201 | 0.857 | 8 | 1.43e−06 | 2.85e−05 |
| Breast cancer | 147 | 0.627 | 7 | 2.19e−06 | 4.09e−05 |
| MicroRNAs in cancer | 299 | 1.28 | 9 | 2.9e−06 | 4.98e−05 |
| Endocrine resistance | 98 | 0.418 | 6 | 2.97e−06 | 4.98e−05 |
| Hepatitis B | 163 | 0.695 | 7 | 4.36e−06 | 6.94e−05 |
| Central carbon metabolism in cancer | 65 | 0.277 | 5 | 7.09e−06 | 0.000107 |
| Non-small cell lung cancer | 66 | 0.282 | 5 | 7.64e−06 | 0.00011 |
| Thyroid hormone signaling pathway | 116 | 0.495 | 6 | 7.94e−06 | 0.00011 |
| Renal cell carcinoma | 69 | 0.294 | 5 | 9.53e−06 | 0.000126 |
| Prolactin signaling pathway | 70 | 0.299 | 5 | 1.02e−05 | 0.00013 |
| Oocyte meiosis | 125 | 0.533 | 6 | 1.22e−05 | 0.000149 |
| Pancreatic cancer | 75 | 0.32 | 5 | 1.44e−05 | 0.000169 |
| Epstein-Barr virus infection | 201 | 0.857 | 7 | 1.73e−05 | 0.00019 |
| Proteoglycans in cancer | 201 | 0.857 | 7 | 1.73e−05 | 0.00019 |
| Measles | 138 | 0.589 | 6 | 2.15e−05 | 0.000228 |
| ErbB signaling pathway | 85 | 0.363 | 5 | 2.65e−05 | 0.000272 |
| Small cell lung cancer | 93 | 0.397 | 5 | 4.1e−05 | 4e−04 |
| Hepatitis C | 155 | 0.661 | 6 | 4.15e−05 | 4e−04 |
| T cell receptor signaling pathway | 101 | 0.431 | 5 | 6.09e−05 | 0.00057 |
| PI3K-Akt signaling pathway | 354 | 1.51 | 8 | 9e−05 | 0.000818 |